Siya Health

An online ADHD assessment typically costs about $150 to $900 overall, with many common options clustering around $189–$199 for a one-time assessment.[2][4][5][6][7] A few specific examples from current providers: ADHD Online (Mentavi): $199 for a comprehensive assessment evaluated by a licensed psychologist.[1][6] ADHD Online / GoodRx listing: $189 for the assessment.[5][7] Siya Health: $199 flat rate for an adult ADHD evaluation.[10] Broader online screening services often start around $150–$300, while more extensive packages can reach $900.[2][4][11] If you want the cheapest route, a screening-only service may be under $200.[2][4] If you need a more formal diagnostic assessment with a written report, expect closer to $199–$900, depending on the provider and what’s included.[1][3][10][11] If you want, I can also compare which online ADHD assessments are cheapest, best for adults, or most likely to be accepted for diagnosis/medication.

Mentioned in position 4 of 4

An online ADHD assessment typically costs about $150 to $900 in the U.S., with many well-known services charging around $189–$199 for an initial assessment.[3][5][7][9][11] In the UK, private online ADHD assessments commonly start around £495–£695 and can rise to £1,200+ depending on the clinic and what’s included.[1][4][6][13] A few concrete examples: ADHD Online / Mentavi: $189 one-time assessment.[5][7][11] Siya Health: $199 flat-rate adult evaluation.[9] Online ADHD Clinics UK: about £500–£1,200 for a comprehensive assessment with a report.[6] ADHD Centre UK: £695 for an online assessment that includes diagnosis and a written report.[4] Price depends mainly on whether you’re getting a screening or a full diagnostic evaluation. Quick online screenings can be as low as $150–$300, while more comprehensive assessments with clinical interviews, questionnaires, and written reports are usually higher.[3][12][15][16] If you want, I can also compare the cheapest reputable options by country or insurance vs self-pay.

Mentioned in position 3 of 5

An online ADHD assessment typically costs $189 to $900 in the United States, with many popular platforms like ADHD Online setting the price at a specific $189 for a comprehensive psychologist-reviewed questionnaire[3][5][6]. In the UK, basic online assessments start around £495 for adults and £795 for children, ranging up to £2,850 for comprehensive evaluations[1][4]. Key Cost Breakdown by Region and Service Type Region/Service Type Price Range Notable Examples US – Initial Screening $150 – $300 Quick, accessible screenings; may not yield a formal diagnosis for all accommodations[3][6] US – Full Online Diagnosis $189 – $900 ADHD Online ($189), Siya Health ($199)[5][9] US – Comprehensive In-Person $1,000 – $5,000+ Neuropsychological evaluations with detailed reports[3][16] UK – Adult Online £495 – £695 The ADHD Centre (£695), various clinics from £495[1][4] UK – Child Online £695 – £795 Child assessments often start higher than adults[1] Canada $279 – $1,000+ Maple ($279 for assessment step); psychologists often charge $1,000–$2,500[11] Australia $540 – $675 ADHD Therapy ($540 adults, $675 children)[14] Important Considerations Free Screenings: Some services like ADHD Advisor and Cerebral offer free initial self-tests to determine if a full assessment is necessary, though ongoing treatment starts at a monthly fee[6]. Insurance: If you have insurance, costs may drop to a copay of ~$30 per visit, whereas cash-only platforms charge the full $189+ upfront[13]. Diagnosis Validity: Quick online screenings ($150–$300) may not be accepted for school accommodations or disability services, whereas the $189 ADHD Online assessment is widely cited as a standard for a verified medical diagnosis accepted by physicians[3][6]. What’s Included: Higher-priced packages (up to $900 or £2,850) typically include clinical interviews, cognitive testing (e.g., QbCheck), and detailed written reports, while basic assessments may only include a questionnaire[2][6].

Mentioned in position 2 of 7

Controlled substance rules make online ADHD prescriptions more restrictive than non-stimulant treatments because ADHD stimulants (e.g., Adderall, Ritalin, Vyvanse) are classified as Schedule II controlled substances, triggering strict federal and state regulations. However, under current federal flexibilities extended through December 31, 2026, patients can still obtain these prescriptions online without a prior in-person visit, provided they have a real-time video evaluation with a DEA-registered provider licensed in their state[1][3][4]. Key Impacts of Controlled Substance Rules: Requirement Detail In-person visit Not required for new patients under current federal flexibilities (extended to Dec 31, 2026) [3][4] Video vs. audio-only Video visit mandatory; audio-only is insufficient for Schedule II prescriptions [4] Provider licensure Must be licensed in the patient’s state and DEA-registered [1][4][5] Prescription frequency No auto-refills; new prescription required monthly for Schedule II stimulants [5] Electronic prescribing EPCS (electronic prescribing) mandatory in most states, including California [5][14] PDMP checks Providers must check Prescription Drug Monitoring Programs before prescribing [6][11] State-specific rules Some states (e.g., California) require informed consent and CURES reporting within 1 business day [5] Important Caveats: The DEA has proposed permanent rules that would eventually require an initial in-person evaluation or a referral from one who did, which could significantly limit direct-to-consumer telemedicine for ADHD stimulants if finalized [2][12]. Providers would also need to be physically located in the same state as the patient and issue at least 50% of prescriptions after in-person visits under proposed rules [2][8]. Legitimate online ADHD clinics (e.g., Klarity, MEDvidi, Siya Health) comply with these rules by conducting thorough video evaluations, verifying identity, and monitoring for misuse [4][11][13]. In summary, while online ADHD prescribing remains accessible now, it operates under tighter oversight than non-controlled medications, and future rule changes could tighten access significantly.

Mentioned in position 3 of 3